Providers who offer both GLP-1 treatments and cosmetic injectables often see higher patient retention
Any savings on health spending because of obesity drugs may take many years and may not accrue to the Medicaid program if individuals experience shifts in coverage, so states may not be factoring long-term savings into coverage decisions
One limitation regarding this study was that it involved participants with early stages of PD, so while the data suggest that lixisenatide can delay disease progression, the applications are limited to patients in the early stages
Reported Side Effects and Safety Concerns From Unlicensed Use Retatrutide causes predominantly gastrointestinal side effects, with additional class-level risks including pancreatitis, gallbladder disease, heart rate elevation, and injection site infections
Your gel packs melted early If your gel packs melt before you reach your destination, assess the situation before panicking
Without specific proof as to the exact cause of why a GLP-1 could cause a higher risk of developing NAION, we can hypothesize a bit and suggest hypovolemia and dehydration from perhaps weight loss, especially if the patient is getting a medication for hypertension and the weight loss has reduced the need for the hypertensive agent and thus the patient develops hypotension
